High-dose α-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy

Uma Singh, James Otvos, Amitava Dasgupta, James A. De Lemos, Sridevi Devaraj, Ishwarlal Jialal

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Subfractions of HDL, particularly large HDL (HDL2), are inversely correlated with the severity of coronary artery disease (CAD). α-Tocopherol (AT) is the main lipid-soluble antioxidant in plasma. Results of a previous small study (n = 44) suggested that either a combination of an antioxidant cocktail [800 IU/day 2R,4′R,8′R-(RRR)-AT plus 1 g vitamin C, 25 mg β-carotene, and 100 μg selenium] or individual antioxidant vitamins combined with simvastatin-niacin (S-N) therapy attenuated the protective increase in HDL2 seen with S-N alone. Few data are available on the effect of AT therapy alone on HDL subfractions, which we addressed in this study. Methods: In a prospective placebo-controlled study, we randomized 127 patients with stable CAD to receive high-dose RRR-AT (1200 IU/day for 2 years) or placebo. HDL subfractions (small, medium, and large HDL particles) were analyzed by nuclear magnetic resonance spectroscopy. Results: AT concentrations significantly increased in the AT arm but not with placebo. No differences were noted between AT and placebo groups in concentrations of total cholesterol, triglyceride, LDL-cholesterol, or HDL-cholesterol. AT therapy did not affect total, small, medium, or large HDL particles compared with baseline or placebo. Furthermore, serum apolipoprotein A1 concentrations did not change after 2 years AT therapy as compared with baseline. Conclusions: High-dose AT therapy administered for a 2-year period does not negatively affect either HDL subfractions or apolipoprotein A1 in patients with CAD on statin therapy. Thus the negative interaction previously proposed between antioxidant cocktail and statin therapy cannot be attributed to AT.

Original languageEnglish (US)
Pages (from-to)525-528
Number of pages4
JournalClinical Chemistry
Volume53
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Tocopherols
Coronary Artery Disease
Antioxidants
Simvastatin
Niacin
Apolipoprotein A-I
Placebos
Carotenoids
Therapeutics
Selenium
Vitamins
LDL Cholesterol
HDL Cholesterol
Nuclear magnetic resonance spectroscopy
Ascorbic Acid
Cholesterol
Lipids
Plasmas
Triglycerides

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

High-dose α-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy. / Singh, Uma; Otvos, James; Dasgupta, Amitava; De Lemos, James A.; Devaraj, Sridevi; Jialal, Ishwarlal.

In: Clinical Chemistry, Vol. 53, No. 3, 03.2007, p. 525-528.

Research output: Contribution to journalArticle

Singh, Uma ; Otvos, James ; Dasgupta, Amitava ; De Lemos, James A. ; Devaraj, Sridevi ; Jialal, Ishwarlal. / High-dose α-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy. In: Clinical Chemistry. 2007 ; Vol. 53, No. 3. pp. 525-528.
@article{989b4b0825af4842b73daab43fd90ebd,
title = "High-dose α-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy",
abstract = "Background: Subfractions of HDL, particularly large HDL (HDL2), are inversely correlated with the severity of coronary artery disease (CAD). α-Tocopherol (AT) is the main lipid-soluble antioxidant in plasma. Results of a previous small study (n = 44) suggested that either a combination of an antioxidant cocktail [800 IU/day 2R,4′R,8′R-(RRR)-AT plus 1 g vitamin C, 25 mg β-carotene, and 100 μg selenium] or individual antioxidant vitamins combined with simvastatin-niacin (S-N) therapy attenuated the protective increase in HDL2 seen with S-N alone. Few data are available on the effect of AT therapy alone on HDL subfractions, which we addressed in this study. Methods: In a prospective placebo-controlled study, we randomized 127 patients with stable CAD to receive high-dose RRR-AT (1200 IU/day for 2 years) or placebo. HDL subfractions (small, medium, and large HDL particles) were analyzed by nuclear magnetic resonance spectroscopy. Results: AT concentrations significantly increased in the AT arm but not with placebo. No differences were noted between AT and placebo groups in concentrations of total cholesterol, triglyceride, LDL-cholesterol, or HDL-cholesterol. AT therapy did not affect total, small, medium, or large HDL particles compared with baseline or placebo. Furthermore, serum apolipoprotein A1 concentrations did not change after 2 years AT therapy as compared with baseline. Conclusions: High-dose AT therapy administered for a 2-year period does not negatively affect either HDL subfractions or apolipoprotein A1 in patients with CAD on statin therapy. Thus the negative interaction previously proposed between antioxidant cocktail and statin therapy cannot be attributed to AT.",
author = "Uma Singh and James Otvos and Amitava Dasgupta and {De Lemos}, {James A.} and Sridevi Devaraj and Ishwarlal Jialal",
year = "2007",
month = "3",
doi = "10.1373/clinchem.2006.078865",
language = "English (US)",
volume = "53",
pages = "525--528",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "3",

}

TY - JOUR

T1 - High-dose α-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy

AU - Singh, Uma

AU - Otvos, James

AU - Dasgupta, Amitava

AU - De Lemos, James A.

AU - Devaraj, Sridevi

AU - Jialal, Ishwarlal

PY - 2007/3

Y1 - 2007/3

N2 - Background: Subfractions of HDL, particularly large HDL (HDL2), are inversely correlated with the severity of coronary artery disease (CAD). α-Tocopherol (AT) is the main lipid-soluble antioxidant in plasma. Results of a previous small study (n = 44) suggested that either a combination of an antioxidant cocktail [800 IU/day 2R,4′R,8′R-(RRR)-AT plus 1 g vitamin C, 25 mg β-carotene, and 100 μg selenium] or individual antioxidant vitamins combined with simvastatin-niacin (S-N) therapy attenuated the protective increase in HDL2 seen with S-N alone. Few data are available on the effect of AT therapy alone on HDL subfractions, which we addressed in this study. Methods: In a prospective placebo-controlled study, we randomized 127 patients with stable CAD to receive high-dose RRR-AT (1200 IU/day for 2 years) or placebo. HDL subfractions (small, medium, and large HDL particles) were analyzed by nuclear magnetic resonance spectroscopy. Results: AT concentrations significantly increased in the AT arm but not with placebo. No differences were noted between AT and placebo groups in concentrations of total cholesterol, triglyceride, LDL-cholesterol, or HDL-cholesterol. AT therapy did not affect total, small, medium, or large HDL particles compared with baseline or placebo. Furthermore, serum apolipoprotein A1 concentrations did not change after 2 years AT therapy as compared with baseline. Conclusions: High-dose AT therapy administered for a 2-year period does not negatively affect either HDL subfractions or apolipoprotein A1 in patients with CAD on statin therapy. Thus the negative interaction previously proposed between antioxidant cocktail and statin therapy cannot be attributed to AT.

AB - Background: Subfractions of HDL, particularly large HDL (HDL2), are inversely correlated with the severity of coronary artery disease (CAD). α-Tocopherol (AT) is the main lipid-soluble antioxidant in plasma. Results of a previous small study (n = 44) suggested that either a combination of an antioxidant cocktail [800 IU/day 2R,4′R,8′R-(RRR)-AT plus 1 g vitamin C, 25 mg β-carotene, and 100 μg selenium] or individual antioxidant vitamins combined with simvastatin-niacin (S-N) therapy attenuated the protective increase in HDL2 seen with S-N alone. Few data are available on the effect of AT therapy alone on HDL subfractions, which we addressed in this study. Methods: In a prospective placebo-controlled study, we randomized 127 patients with stable CAD to receive high-dose RRR-AT (1200 IU/day for 2 years) or placebo. HDL subfractions (small, medium, and large HDL particles) were analyzed by nuclear magnetic resonance spectroscopy. Results: AT concentrations significantly increased in the AT arm but not with placebo. No differences were noted between AT and placebo groups in concentrations of total cholesterol, triglyceride, LDL-cholesterol, or HDL-cholesterol. AT therapy did not affect total, small, medium, or large HDL particles compared with baseline or placebo. Furthermore, serum apolipoprotein A1 concentrations did not change after 2 years AT therapy as compared with baseline. Conclusions: High-dose AT therapy administered for a 2-year period does not negatively affect either HDL subfractions or apolipoprotein A1 in patients with CAD on statin therapy. Thus the negative interaction previously proposed between antioxidant cocktail and statin therapy cannot be attributed to AT.

UR - http://www.scopus.com/inward/record.url?scp=33947373911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947373911&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2006.078865

DO - 10.1373/clinchem.2006.078865

M3 - Article

VL - 53

SP - 525

EP - 528

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 3

ER -